Published in Blood on January 21, 2014
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity (2015) 1.92
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia. Oncotarget (2015) 0.80
Survival in acute myeloid leukemia is associated with NKp44 splice variants. Oncotarget (2016) 0.78
Roles of CD48 in regulating immunity and tolerance. Clin Immunol (2016) 0.78
KIR B or not to be?...that is the question for ALL. Blood (2014) 0.76
The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity. Oncotarget (2016) 0.76
Signaling Lymphocytic Activation Molecule Family Receptor Homologs in New World Monkey Cytomegaloviruses. J Virol (2015) 0.76
Immunomodulatory drugs II: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets (2015) 0.75
NK Cell Exhaustion. Front Immunol (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res (2004) 19.32
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Acute myeloid leukaemia. Lancet (2006) 7.74
Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc (2006) 6.24
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24
Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature (2001) 4.76
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood (1999) 4.58
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med (2012) 4.52
NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood (1991) 4.30
HDAC family: What are the cancer relevant targets? Cancer Lett (2008) 4.17
NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med (1998) 3.83
A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells (2007) 3.62
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature (2009) 3.37
Immune functions encoded by the natural killer gene complex. Nat Rev Immunol (2003) 3.21
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med (1998) 3.09
The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell (1993) 2.96
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol (2001) 2.60
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol (2005) 2.55
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 2.50
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood (1991) 2.33
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20
2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med (2004) 1.88
Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol (2006) 1.74
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res (2005) 1.73
Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol (2000) 1.66
Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol (2005) 1.41
Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 1.37
An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe (2011) 1.28
Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol (2007) 1.27
Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw (2013) 1.26
Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood (2013) 1.25
Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep (2013) 1.22
2B4-mediated activation of human natural killer cells. Mol Immunol (2000) 1.13
How to manage acute promyelocytic leukemia. Leukemia (2012) 1.13
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
Natural killer cell immune escape in acute myeloid leukemia. Leukemia (2012) 1.10
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer (2011) 1.09
Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. J Immunol (2003) 1.09
Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia (1996) 0.99
2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness. Immunology (2000) 0.98
Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene (1998) 0.97
The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene (2011) 0.94
The murine NK receptor 2B4 (CD244) exhibits inhibitory function independent of signaling lymphocytic activation molecule-associated protein expression. J Immunol (2004) 0.92
Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun (2006) 0.89
Battle of the midgets: innate microRNA networking. RNA Biol (2012) 0.85
Mutational analysis of the human 2B4 (CD244)/CD48 interaction: Lys68 and Glu70 in the V domain of 2B4 are critical for CD48 binding and functional activation of NK cells. J Immunol (2005) 0.84
Targeting expression of the leukemogenic PML-RARα fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell differentiation and apoptosis. Hum Gene Ther (2011) 0.83
Leukemia-lymphoma cell lines as model systems for hematopoietic research. Ann Med (2003) 0.82
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med (2006) 6.54
Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity (2008) 6.49
Host immune system gene targeting by a viral miRNA. Science (2007) 5.10
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol (2006) 5.00
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe (2009) 3.59
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol (2008) 3.14
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol (2005) 2.55
Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 2.53
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells (2005) 2.24
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol (2012) 2.13
The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood (2003) 2.06
Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica (2007) 1.95
CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med (2007) 1.82
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.77
NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut (2011) 1.75
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol (2013) 1.70
Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol (2013) 1.65
CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood (2003) 1.62
Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58
Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol (2004) 1.57
The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol (2009) 1.54
The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol (2004) 1.53
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation. Mol Cell (2012) 1.52
The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. J Urol (2007) 1.50
Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol (2006) 1.48
The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol (2010) 1.48
Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2008) 1.47
The unique properties of uterine NK cells. Am J Reprod Immunol (2010) 1.46
Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol (2009) 1.44
The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J Immunol (2009) 1.44
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma (2014) 1.42
CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol (2002) 1.34
Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci U S A (2012) 1.30
Enhanced recognition of human NK receptors after influenza virus infection. J Immunol (2003) 1.29
An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe (2011) 1.28
Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res (2003) 1.25
MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res (2012) 1.23
An integrated view of the regulation of NKG2D ligands. Immunology (2009) 1.23
Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol (2003) 1.23
MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol (2004) 1.22
Analysis of human cytomegalovirus-encoded microRNA activity during infection. J Virol (2009) 1.22
Direct recognition of Fusobacterium nucleatum by the NK cell natural cytotoxicity receptor NKp46 aggravates periodontal disease. PLoS Pathog (2012) 1.22
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol (2007) 1.21
The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol (2005) 1.21
Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol (2004) 1.20
Recruitment of MHC class I molecules by tapasin into the transporter associated with antigen processing-associated complex is essential for optimal peptide loading. J Immunol (2002) 1.18
Endometrial NK cells are special immature cells that await pregnancy. J Immunol (2008) 1.18
Tumor immunoediting by NKp46. J Immunol (2010) 1.18
The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol (2002) 1.17
Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest (2002) 1.14
Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins. J Virol (2008) 1.14
Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood (2003) 1.13
Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene (2003) 1.12
Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology (2007) 1.12
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol (2013) 1.11
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol (2005) 1.11
Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet (2013) 1.10
When killers become helpers. Trends Immunol (2007) 1.09
Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol (2012) 1.09
MiRNA-mediated control of HLA-G expression and function. PLoS One (2012) 1.08
H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J Virol (2007) 1.08
Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood (2005) 1.07
Expression of KIR2DL1 on the entire NK cell population: a possible novel immunodeficiency syndrome. Blood (2004) 1.07
Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cell Mol Life Sci (2012) 1.06
Expression and function of CD300 in NK cells. J Immunol (2010) 1.06
Dynamic behavior of NK cells during activation in lymph nodes. Blood (2009) 1.04
Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function. Infect Immun (2007) 1.03
Killing of avian and Swine influenza virus by natural killer cells. J Virol (2010) 1.03
Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology (2004) 1.02
Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol (2011) 1.01
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood (2003) 1.00
Paired NK cell receptors controlling NK cytotoxicity. FEBS Lett (2010) 1.00
Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma. Hematol Oncol (2011) 1.00
Intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor 1. J Immunol (2007) 1.00
CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway. J Biol Chem (2006) 0.99
Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface. PLoS One (2010) 0.96
Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol (2006) 0.95
Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS One (2012) 0.94
Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol (2007) 0.93
The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J Immunol (2004) 0.92
The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk. PLoS One (2011) 0.92